The two measles virus (MV) envelope glycoproteins, the hemagglutinin (H) and the fusion (F) protein, are targets for immune recognition by the immune system of an infected human host (for reviews, see references 29, 34, and 38). The generation of biologically active antibodies against the glycoproteins, i.e., hemagglutination-and fusion-inhibiting antibodies and neutralizing antibodies induced by either infection with wild-type virus or vaccination with a live attenuated vaccine, usually confers lifelong protective immunity against measles (4, 9, 12, 24, 25, 36, 46, 57, 59 ).
The failure of inactivated measles virus vaccines used thus far to protect against measles upon reexposure to the virus has been associated with an incomplete immune response against the F protein (32, 33, 35, 37) . This illustrates the importance of the presentation of F in an immunogenic form in future inactivated vaccines (33) . The rationale and the demands for the development of inactivated vaccines against measles have recently been formulated by a World Health Organization steering committee.
Identification of the immunogenic epitopes which are recognized by B-and T-lymphocyte antigen receptors may be of crucial importance for vaccine development. CD4+ T lymphocytes which assist in the activation of B lymphocytes and in their differentiation to antibody-producing cells recognize processed fragments of endocytosed protein antigen presented by class II molecules of the major histocompatibility complex at the surface of antigen-presenting cells (APC). CD8+ cytotoxic T lymphocytes (CTL) eliminate virus-infected cells, since they express at their cell surface processed fragments of endogenously synthesized viral proteins which associate with class I major histocompatibility complex molecules (for reviews, see references 2, 50, and 61).
For a number of virus infections, including MV infection, * Corresponding author.
a major role in eliminating virus-infected cells has also been attributed to CD4+ class II-restricted CTL (11, 17, 18, 26, 47, 60) . However, we recently documented the predominance of CD8+ class I-restricted CTL in antiviral T-lymphocyte-mediated immunity (53) . In the present study, the epitope specificity and HLA restriction of cloned F protein-specific human CTL were documented. With ,B-galactosidase fusion proteins expressing different regions of F and a number of synthetic peptides, nonameric and decameric sequences representing class Iand class II-presentable epitopes clustering between amino acids (aa) 379 and 466 could be identified.
MATERIALS AND METHODS
Antigen preparations. (i) MV. Plaque-purified MV (Edmonston B strain) was cultured on Vero cells, and 107 50% tissue culture infective doses of MV per ml was routinely used to infect human Epstein-Barr virus-transformed B-lymphoblastoid cell lines (B-LCL).
(ii) F. The F protein was purified from whole virus by solubilizing purified MV with octyl 3-D-glucopyranoside (2% [wtlvol] octyl glucoside; Sigma Chemical Co., St. Louis, Mo.) and subjecting the resulting preparation to affinity chromatography with F-specific monoclonal antibody 7-21 coupled to CNBr-activated Sepharose 4B as described previously (6).
(iii) F-13-galactosidase fusion proteins. 3-Galactosidase fusion proteins containing both the 3-galactosidase protein and combined C-and N-terminal fractions of F were expressed in Escherichia coli AB1157 from pEX3 constructs as previously described (8) 10 ,000 rpm [Sorvall SS-34 rotor]), the pellet was resuspended in 0.1% Triton X-100-10 mM Tris-HCl-0.1 mM EDTA (pH 7.5). Triton X-100 was removed by centrifugation of the proteins through a 20% sucrose cushion (10 min at 10,000 rpm [Sorvall SS-34 rotor]). The pellets were resuspended in phosphate-buffered saline (PBS) solution (pH 7.2) and sonicated before they were used in proliferative T-cell assays. About 90% of the total protein in these preparations consisted of fusion proteins, as determined by SDS-PAGE and Western blot analysis.
(iv) F peptides. Peptides were assembled with an automated multiple peptide synthesizer equipped with a 48-column reaction block (AMS 422; ABIMED Analysen-Technik GmbH, Langenfeld, Germany) and Noa-fluorenylmethoxycarbonyl (Fmoc)-protected (1, 10) amino acids (Novabiochem, Laufelfingen, Switzerland) as previously described (58) . All peptides were prepared with acetylated N termini and C-terminal carboxamides. The peptides were deprotected and cleaved from the solid support (58) with trifluoroacetic acid in the presence of scavengers (as described in reference 1 but with a slight modification, i.e., water replaced the recommended phenol). The crude peptides (purity of 50 to 90% for 18-meric peptides and >85% for 12-meric peptides, as determined by reverse-phase high-performance liquid chromatography analysis) were used in immunological experiments in concentrations of 10-9 to 10-5 M.
T-cell clones. The MV-specific human T-cell clones described in this article were established from peripheral blood mononuclear cells (PBMC) of three healthy adult individuals (donors 3, 4, and 5) and of two children (donors 1 and 2). PBMC were obtained from the children 4 weeks after clinical symptoms of measles were observed. All T-cell clones were generated from PBMC that were stimulated and cloned with autologous MV-infected B-LCL and were cultured in vitro as previously described (52, 53 ; some of the T-cell clones previously described have been renamed, and information regarding this redesignation can be obtained from corresponding author). Briefly, the T-cell clones were maintained in culture in 96-well round-bottomed microtiter plates (Greiner Labor Technik, Nurtingen, Germany) in 150 ,ul of RPMI 1640 supplemented with 10% (vol/vol) pooled human AB serum, 2 mM L-glutamine, penicillin (100 U/ml), strep- tomycin (100 ,ug/ml), 10- 
RESULTS
Generation of F glycoprotein-specific CTL clones. F-specific T-cell clones were generated in vitro from PBMC of five individuals by using autologous MV-infected B-LCL as APC. Although these procedures can yield clones recognizing different polypeptides of MV (52) , all T-cell clones derived from two donors (3 and 5) and some of the clones from three other donors (1, 2, and 4) appeared to recognize F. The present study focused on the identification of the specificities of six of these F-specific T-cell clones. Among these clones are four CD4+ T-cell clones (3-F94, 5-F2.1, 4-F76, and 4-F99) derived from three healthy adult individuals and two CD8+ T-cell clones (1-F20 and 2-F40) that were generated from PBMC obtained from two children 4 weeks after the onset of clinical symptoms of measles.
All T-cell clones showed an F-specific proliferative T-cell response to APC that were either pulsed with affinitypurified F or infected with vaccinia virus expressing F (vv-F37) ( Table 1) .
Analyses of the genetic restriction of antigen presentation revealed that the response of CD4+ T-cell clone 3-F94 is restricted to HLA-DRw53 of the DR4 or DR7 ( Definition of the regions of F recognized by F-specific T-cell clones. In order to enable the identification of localization of T-cell epitopes that are recognized by F-specific T-cell clones, we constructed a set of 3-galactosidase fusion proteins, containing various F amino acid sequences of different lengths. All HLA class II-restricted F-specific T-cell clones showed a proliferative T-cell response to the 13-galactosidase fusion protein containing the major part of F (aa 2 to 513) (Fig. 1) (Fig. 3) . The (Fig. 4, experiment 1) . Depending on the outcome of this experiment, a second set of nested peptides with combined C-and N-terminal deletions were synthesized in order to define the actual minimal sequence of these peptides that could be presented to these clones (Fig. 4,  experiment 2 ). From these experiments, it can be concluded that the minimal peptide sequence efficiently recognized by clone 4-F99 is the nonapeptide EVNGVTIQV, representing aa 427 to 435 of F (Fig. 4) . The minimal peptide recognized by clone 3-F94 turned out to be the decamer PISLERLDVG, representing aa 454 to 463 of F, and this peptide was as efficiently recognized as the longer ones covering this sequence (Fig. 4) . Although the amino acid proline at the first position of the 11-mer PISLERLDVGT can be deleted, the resulting peptide ISLERLDVGT required at least a 10-foldhigher peptide concentration to sensitize targets for killing by the clone. Deletion of this residue in the decamer PISL-ERLDVG, resulting in peptide ISLERLDVG, abolished the capacity to be recognized by clone 3-F94 (Fig. 4) .
The nonapeptide RRYPDAVYL is recognized by clone 2-F40 and shows considerable homology to other HLA-B27 binding peptides. Among the HLA class I-restricted F-specific CTL clones that were generated from the PBMC of children with acute measles, clone 2-F40 recognized an F epitope presented by HLA-B27 molecules. Amino acid sequence analyses of endogenous peptides isolated from HLA-B27 molecules and of viral peptides which bind to HLA-B27 molecules have revealed a peptide binding motif for HLA-B27 molecules (20) . This motif is characterized by an arginine found in all such peptides at position 2 and by a preference for charged amino acids at positions 1 (Fig. 6 ). Additionally, a hydrophobic residue was found at position 9. Thus the sequence consisting of aa 379 to 463 of F contains three T-cell epitopes that all have common features of class II binders: hydrophobic residues at positions 1 and/or 2 and at position 9.
On the basis of analysis of the T-cell response in MVseropositive adults and in a patient with multiple sclerosis, it has been argued that CTL directed against MV are primarily CD4+ class II restricted (17, 18) , despite earlier analyses of the T-cell response toward MV which showed evidence for CD8+ class I-restricted CTL activity against MV (21, 23, 48) . Recently we have demonstrated that in recovery from acute measles, CD8+ class I-restricted CTL are the predominant MV-specific effector cells (53) . Moreover, we showed that CD8+ class I-restricted MV-specific CTL can also be cloned from healthy MV-seropositive adults (52) . One of the CTL clones, 2-F40 (from a patient with acute measles), showed an HLA-B27-restricted recognition of F (Fig. 5) . A search based on a known HLA-B27 binding peptide motif revealed a nonamer sequence in F (aa 438 to 446) consistent with such a motif (20) . This sequence, RRYPDAVYL, contains an arginine anchor at position 2, another arginine at position 1, a tyrosine at position 3, and a small hydrophobic residue on position 6 (Fig. 6) . Using the set of 12-mer peptides with a 3-aa overlap spanning this sequence, we found that only the peptide containing this entire nonamer sequence sensitized targets for killing by the CTL clone. Subsequently, we showed that it was indeed the nonapeptide that contained the core sequence (Fig. 5) (7, 27, 28, 39, 51, 55, 56) and can prime for class I-restricted CTL (13, 30, 49) , indicate the potential of an ISCOM-based vaccine containing F in addition to other structural proteins of MV.
